Contineum Therapeutics, Class Stock Today
| CTNM Stock | 7.76 0.59 8.23% |
PerformanceVery Weak
| Odds Of DistressLow
|
Contineum Therapeutics, is selling at 7.76 as of the 25th of March 2025; that is 8.23 percent up since the beginning of the trading day. The stock's lowest day price was 7.18. Contineum Therapeutics, has about a 21 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 25th of December 2024 and ending today, the 25th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 5th of April 2024 | Category Healthcare | Classification Health Care |
Contineum Therapeutics, is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 19.14 M outstanding shares of which 848.41 K shares are currently shorted by private and institutional investors with about 15.43 trading days to cover. More on Contineum Therapeutics, Class
Moving together with Contineum Stock
| 0.75 | CDIOW | Cardio Diagnostics | PairCorr |
| 0.95 | VINC | Vincerx Pharma Earnings Call This Week | PairCorr |
| 0.75 | ELVN | Enliven Therapeutics | PairCorr |
Moving against Contineum Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Contineum Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO and Presidentident | MS MBA | ||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Contineum Therapeutics, can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Contineum Therapeutics,'s financial leverage. It provides some insight into what part of Contineum Therapeutics,'s total assets is financed by creditors.
| |||||
Contineum Therapeutics, Class (CTNM) is traded on NASDAQ Exchange in USA. It is located in 10578 Science Center Drive, San Diego, CA, United States, 92121 and employs 41 people. Contineum Therapeutics, is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 200.76 M. Contineum Therapeutics, conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 19.14 M outstanding shares of which 848.41 K shares are currently shorted by private and institutional investors with about 15.43 trading days to cover.
Contineum Therapeutics, generates negative cash flow from operations
Check Contineum Therapeutics, Probability Of Bankruptcy
Ownership AllocationContineum Therapeutics, holds a total of 19.14 Million outstanding shares. The majority of Contineum Therapeutics, Class outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Contineum Therapeutics, to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Contineum Therapeutics,. Please pay attention to any change in the institutional holdings of Contineum Therapeutics, Class as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Contineum Ownership Details
Contineum Therapeutics, Historical Income Statement
Contineum Stock Against Markets
Contineum Therapeutics, Corporate Management
| John Healy | General Secretary | Profile | |
| Steve Kunszabo | Senior Communications | Profile | |
| Austin Chen | Senior Research | Profile | |
| Morgan Paulsen | Senior Accounting | Profile | |
| Julie Iwashita | Senior Operations | Profile | |
| Peter CPA | Chief Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Contineum Therapeutics, Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Contineum Therapeutics,. If investors know Contineum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Contineum Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Contineum Therapeutics, is measured differently than its book value, which is the value of Contineum that is recorded on the company's balance sheet. Investors also form their own opinion of Contineum Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Contineum Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Contineum Therapeutics,'s market value can be influenced by many factors that don't directly affect Contineum Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Contineum Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Contineum Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Contineum Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.